Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
暂无分享，去创建一个
G. Fuller | J. Huse | G. Rao | P. Sharma | J. D. de Groot | J. Blando | J. Allison | Ying Yuan | Shouhao Zhou | A. Heimberger | F. Lang | W. Yung | R. Sawaya | S. Prabhu | I. McCutcheon | R. Colen | S. Yadav | Jimin Wu | J. Weinberg | M. Penas-Prado | L. Vence | J. Mandel | S. Ferguson | B. Pei | M. Loghin | B. O'Brien | S. Weathers | K. Hunter | Kristin D Alfaro-Munoz | B. O’Brien | Carlos Kamiya Matsouka | Shiao-Pei Weathers